Results 111 to 120 of about 13,844,580 (194)

Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity

The Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Topiramate (TPM) is used to treat seizures in adults and children ≥2 years. In children, TPM dosing is body weight based. It is unknown whether children with obesity may benefit from an alternative dosing strategy. We developed a novel physiologically based pharmacokinetic (PBPK) model for TPM that accounts for age‐ and obesity‐related changes
Patricia D. Maglalang, Daniel Gonzalez, William J. Muller, Chi D. Hornik, Stuart L. Goldstein, Mobeen Rathore, Jennifer L. Ford, Stephen J. Balevic, Jaydeep Sinha, Andrea Edginton, Rachel G. Greenberg, Daniel K. Benjamin, Jia‐Yuh Chen, Kanecia O. Zimmerman, the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee   +14 more
wiley   +1 more source

omrichfield/PACE-PBPK-Monte-Carlo__public: PACE-PBPK-Monte-Carlo__public

Public Physiologically Based Pharmacokinetic Model of polyamine coester ...
omrichfield
core   +1 more source

Workflow of the rabbit PBPK/TK model development.

, 2018
Starting with a generic mammalian PBPK model on top, rabbit specific physiology parameters are added (first level). Next, physicochemistry from a compound (second level), followed by information regarding active processes (third level) are introduced ...
Sebastian Schneckener (436626), Panteleimon D. Mavroudis (4990031), Donato Teutonico (4990037), Helen E. Hermes (4990034), Thomas G. Preuss (535313)   +4 more
core   +1 more source

Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib

CPT: Pharmacometrics & Systems Pharmacology
Adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non–small‐cell lung cancer (NSCLC) are treated with 600 mg alectinib twice daily (BID) as first‐line treatment.
Tamara vanDonge, Elena Guerini, Amaury O'Jeanson, Neil Parrott, Clare Devlin, Cordula Stillhart, Nassim Djebli   +6 more
doaj   +1 more source

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

The model schema of the mechanistically based PBPK/PD model details at the liver.

, 2019
The IFN-α is cleared via the binding to the respective receptors in the liver. The binding of IFN-α to the IFNAR2 and IFNAR1 takes place in the interstitium of the liver (M1-M5), hence activating the JAK/STAT pathway leading to the activation of mRNAc of
Jörg Lippert (124210), Julian Brandl (3840103), Sven Sahle (222858), Lars Küpfer (6331121), Priyata Kalra (6331118), Christoph Niederalt (535381), Ursula Kummer (437648), Thomas Gaub (223638)   +7 more
core   +1 more source

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis

Frontiers in Pharmacology
Introduction: Streptococcus suis (S. suis) is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against S. suis.
Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang   +15 more
doaj   +1 more source

Integrating a Tumor Size‐Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody‐Drug Conjugates in Non‐Small Cell Lung Cancer

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Antibody‐drug conjugate (ADC) development in solid tumors faces efficacy and safety challenges from heterogeneous target expression, limited tumor penetration, and off‐target payload exposure. We developed a spatial quantitative systems pharmacology (QSP) framework integrating ADC‐analyte physiologically based pharmacokinetics (PBPK), a Krogh ...
Mehdi Nikfar, Richard Franzese, Herbert Struemper, Brett Howell, Murad Melhem   +4 more
wiley   +1 more source

인체 PBPK 모델을 이용한 DEHP의 노출량 평가

, 2013
학위논문 (석사)-- 서울대학교 보건대학원 : 환경보건학과, 2013. 8. 김성균.Di(2-ethylhexyl)phthalate (DEHP)는 PVC 등 플라스틱 제품의 대표적인 가소제로 광범위하게 사용되는 프탈레이트의 한 종류이다. 본 연구에서는 수용체 장기(organs)의 생리학적 구조와 기능을 바탕으로 화학물질의 흡수 (absorption), 분포 (distribution), 대사 (metabolism) 및 배설 (excretion)을 예측하는
김경민
core  

Prediction variability in physiologically based pharmacokinetic modeling of tissue disposition under deep uncertainty

npj Systems Biology and Applications
Physiologically based pharmacokinetic (PBPK) models are increasingly invoked in virtual screening workflows for therapeutics. These mechanistic models project pharmacokinetic (PK) outcomes from molecular properties, with data-driven models acting as ...
Mustafa Farahat, D. T. Flaherty, Zachary R. Fox, Belinda S. Akpa   +3 more
doaj   +1 more source